AbbVie Inc (NYSE:ABBV) showing jumped of 0.09% and closed at $65.11, after gaining total volume of 3.46 million shares. Its earnings per share (EPS) is $3.65 and its beta value stands at 1.54 points and has total market capitalization of $103.55 billion and a total of 1.59 billion outstanding shares.
AbbVie Inc (ABBV) on March 30, 2017 announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. HUMIRA is now the first-and-only biologic treatment with data on fingernail psoriasis in its U.S. prescribing information.
Fingernail psoriasis affects half of all psoriasis patients.1,2 It is a form of chronic plaque psoriasis characterized by pitting, deformation, thickening, discoloration, pain and separation of the nail from the nail bed.1,3 Nail psoriasis can also contribute to social stigmatization and impact quality of life. 2
“Fingernail psoriasis is often difficult to treat, and we are pleased the FDA recognized the importance of these data so that more healthcare providers can make informed medical decisions when prescribing treatments for those living with psoriasis,” said John Medich, Ph.D., vice president, clinical development, Immunology, AbbVie. “AbbVie’s nearly 20 years of research in immunology provides us with in-depth knowledge of challenging diseases and allows us to identify ways to address them – it is our hope that the fingernail psoriasis data will support healthcare providers treating this difficult condition.”
The Phase 3 study was dedicated to evaluating fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis. The study demonstrated nearly half of adult patients treated with HUMIRA achieved an assessment of clear or minimal with at least a two-grade improvement from baseline in signs and symptoms of fingernail psoriasis compared to 6.9 percent of placebo patients (p<0.001). No new safety signals for HUMIRA were observed in the study.
In 2008, HUMIRA was FDA approved to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate. These fingernail psoriasis data are included as a third psoriasis study (Study Ps-III) in the plaque psoriasis clinical studies section (14.8) of the HUMIRA label and can be found here.
Scotts Miracle-Gro Co (NYSE:SMG) decreased -0.51% closed at $92.77 and traded with total volume of 295,726.00 shares, while the average trading remained 381,405.00 shares. During last trade its minimum price was $92.51 and it gained the highest price of $93.36. Its market capitalization was $5.54 billion.
Scotts Miracle-Gro Co (SMG) on March 23, 2017 announced The Scotts Miracle-Gro Foundation as the presenting sponsor of The George Barley Water Prize, the world’s largest water prize offering $10 million to the person or team that develops the most cost-effective technology to remove phosphorus from freshwater bodies.
Together through the Barley Prize, the organizations will combat the issue of harmful algal blooms caused by excess phosphorus, which threatens the health of the Everglades and countless other freshwater bodies.
“Nutrient pollution, especially from phosphorus, is a significant and growing crisis that must be solved,” said Jim King, president of The Scotts Miracle-Gro Foundation. “Our company is proud that we became the largest fertilizer manufacturer in the world to remove phosphorus from our fertilizer products, a step we took in 2011. But we knew then, as we still do today, that our decision would have little impact on eliminating harmful algal blooms that continue to plague freshwater bodies around the world. The decision by our Foundation to announce the sponsorship of the George Barley Water Prize on World Water Day is the first step of a multi-year commitment to elevate public awareness of this issue and celebrate the innovation that will help solve it.”
To date, the Barley Prize has attracted more than 100 teams – a community of innovators, scientists and entrepreneurs – from 13 countries. Currently in Stage 1 of four stages, the grand prize will support innovative and cost-effective technologies that will benefit more than 100,000 miles of rivers and streams and close to 2.5 million acres of lakes, reservoirs and ponds.
Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -17.86% and closed at $1.38, with the total traded volume of 48,674.00 shares. During last trade its minimum price was $1.31 and it gained its highest price of $1.68 and has a total of 40.91 million outstanding shares.
On March 9, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce it has formulated a new Cannabis CBD-based pre-workout sports supplement with Forzagen. Additionally, the company’s joint venture with Karmavore Superfoods is off to a good start, and their chocolates (infused with ETST CBD) are selling well.
The company recently announced a joint venture with Nutrition Specialties and Forzagen, (Earth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and Forzagen) where Earth Science Tech and Forzagen will formulate new CBD-based sports products. Earth Science Tech will help develop the market in the United States while Forzagen will develop the market in Mexico and other international accounts. Earth Science Tech, together with Forzagen, have formulated a full-spectrum CBD-based pre-workout supplement called Black Demon 2.0. The supplement was formulated for serious athletes, and is incredibly potent. Forzagen and Earth Science Tech will be splitting both the costs and revenues of Black Demon 2.0, and it is currently in the label design phase. It is expected to be bottled and start selling within Q2 or Q3 of 2017.
“We have seen great success with our non-CBD products in the past, but we are expecting even greater success with Black Demon 2.0,” said Forzagen owner, Jose Bucay, “We’ve already have competitive athletes testing the supplement, and have nothing but positive feedback in regards to Black Demon 2.0. We think we’ve got a true hit in the making.”